|
Guest
|
Most recent articles on angiogenesis in thyroid cancer:
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth
factor receptor (VEGFR) and epidermal growth factor receptor (EGFR)
tyrosine kinases: current status and future directions.
Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A, Bryce
J, Di Maio M, De Maio E, Normanno N, Perrone F.
Oncologist. 2009 Apr;14(4):378-90.
Advances in chemotherapy of differentiated epithelial and medullary
thyroid cancers.
Sherman SI.
sisherma at (no spam) mdanderson.org
J Clin Endocrinol Metab. 2009 May;94(5):1493-9.
A small-molecule triptolide suppresses angiogenesis and invasion of
human anaplastic thyroid carcinoma cells via down-regulation of the
nuclear factor-kappa B pathway.
Zhu W, Ou Y, Li Y, Xiao R, Shu M, Zhou Y, Xie J, He S, Qiu P, Yan G.
Mol Pharmacol. 2009 Apr;75(4):812-9.
InTextoResearch, Baelen, Liège, Wallonie (Wallonia), Belgique
(Belgium) & Agence Wallonne d’Information Scientifique (AWIS) (Marc
Lacroix, scimedweb at (no spam) mail.com) |
|
|
